Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Slides:

Advertisements

Similar presentations

The expression and signaling of FGFR3 in WM cells.

Advertisements

Volume 58, Issue 3, Pages (September 2010)

Enhanced DNA damage in IDH1 mutant glioma cells.

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Cancer mutations in enriched RBP motifs.

FAK overexpression in invasive human breast cancer and DCIS

FAK overexpression in invasive human colon cancer and colon dysplasia.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Frequent alterations identified and potential actionability.

Protein expression profile in a dasatinib-resistant cell line.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

IL6 mRNA is not detected in metastatic prostate cancer cells.

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Pre- and post-vorinostat values of proliferation-associated gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of proliferation-associated.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

VEGF expression in neoplastic and normal prostate tissue.

FGFR3 mutation analysis of a selection of urine samples from patients included with an FGFR3-mutant (MT) tumor. FGFR3 mutation analysis of a selection.

Tamoxifen-treated patients.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Immune responses to 12MP and 6MHP.

Somatic mutational rates and survival analysis of IBD-CRC.

FILM protein signature predicts poor survival in nontreated stage-IB lung adenocarcinoma. FILM protein signature predicts poor survival in nontreated stage-IB.

A, Proportion of variants detected in the MMR genes.

Alkaline Comet assay showing DNA break formation after 6-TG treatment, implying more SSBs generated in MMR+ cells. Alkaline Comet assay showing DNA break.

Nomogram depicting estimates of postprogression survival, including estimates of 6-, 12-, and 24-month OS according to prechemotherapy and postchemotherapy.

Tumor and serum levels of murine IL-12.

Targetable alterations and pathways in TNBCs after NAC

Location of common clinically relevant mutations in EGFR

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Duration of treatment and intervals of radiographic and ctDNA response

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.

Gene expression levels of ESR1 (A), ERBB2 (B), MiK67(C), and PCNA (D) in pre- and postneoadjuvant chemotherapy samples (n = 21). Gene expression levels.

Representative photograph of somatic mutations detected by PCR-SSCP.

Methylation-specific PCR of APC, RASSF1A, and p14ARF genes in bladder tumor and urine DNAs. In the APC gel panel viewed from left to right, the first (TCC34)

Distribution of FGFR aberrancies in urothelial cancers.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Location of the ER mutations and frequencies per cohort.

Selected overview of clinical trials evaluating FGFR signaling–targeted therapies currently under development (monotherapy). Selected overview of clinical.

Detection of mutant alleles using ddPCR.

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

HPLC chromatograms using mobile phase containing CTAB and OSA showing complete separation of: A, phthaloylglutamine and phthaloylisoglutamine authentic.

Kaplan-Meier table analysis of patients with corticobasal degeneration after onset of symptoms; the y axis refers to proportion of patients who are alive.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. Ibrutinib decreases ofatumumab-mediated complement-dependent cytotoxicity. A,

Cellular pharmacology of F-ara-A and Cl-F-ara-A.

A, Proportion for different in silico predictions at the RNA level.

Schedule-dependent impact of costimulated activated T-cell transfer on T-cell reconstitution after tandem stem cell transplant. Schedule-dependent impact.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Frequency and number of KLL-specific clonotypes in tumors from patients with KLL-specific T cells in PBMCs or cultured TILs. A wedge (the length of which.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Presentation transcript:

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Kaplan-Meier analysis of proportion recurrence for patients included with an FGFR3-mutant tumor. X axis depicts the length of time being recurrence-free with consecutive FGFR3 urine results. Y axis depicts the proportion of recurrences detected. Tahlita C.M. Zuiverloon et al. Clin Cancer Res 2010;16:3011-3018 ©2010 by American Association for Cancer Research